We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Univar's NexusAg Chosen For Novozymes' BioYield Distribution
Read MoreHide Full Article
Univar Inc. recently announced that its NexusAg has been selected by Novozymes as the sole distributor for the latter’s downstream BioYield enhancers in Canada. Notably, BioYield enhancers represent a substantial portion of the company’s biological products portfolio. The deal is effective as of the end of June 2019 and excludes BioRise and JumpStart XL offerings.
Novozymes, a leader in bioinnovation, offers unique dedication to enzymes along with microbes. Its product line of BioYield enhancers are derived from naturally occurring microbes. These act as microbial inoculants that complement conventional fertilizers and boost crop yields for the agricultural industry.
NexusAg will provide dedicated sales presence, which will provide superior market intelligence data along with analytics to forecast trends as well as boost growth.
Univar's shares have lost 17.8% in the past year compared with the industry’s 20.7% decline.
In March 2019, Univar provided updates on 2019 view, considering the recently completed buyout of Nexeo Solutions closed on Mar 1, 2019.
For 2019, it expects adjusted EBITDA between $740 million and $760 million on a combined basis. The projected 10-month earnings from the Nexeo Chemicals business and realized synergies are worth roughly $10 million. The company expects to generate $300-$350 million in free cash flow, before one-time integration cost of around $70 million.
Kirkland has an expected earnings growth rate of 8.8% for 2019. The company’s shares have surged 105.3% in the past year.
Ingevity has an expected earnings growth rate of 17.9% for the current year. The company’s shares have rallied 56.6% in a year’s time.
Materion has an expected earnings growth rate of 12.6% for 2019. Its shares have gained 11.6% in a year’s time.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Univar's NexusAg Chosen For Novozymes' BioYield Distribution
Univar Inc. recently announced that its NexusAg has been selected by Novozymes as the sole distributor for the latter’s downstream BioYield enhancers in Canada. Notably, BioYield enhancers represent a substantial portion of the company’s biological products portfolio. The deal is effective as of the end of June 2019 and excludes BioRise and JumpStart XL offerings.
Novozymes, a leader in bioinnovation, offers unique dedication to enzymes along with microbes. Its product line of BioYield enhancers are derived from naturally occurring microbes. These act as microbial inoculants that complement conventional fertilizers and boost crop yields for the agricultural industry.
NexusAg will provide dedicated sales presence, which will provide superior market intelligence data along with analytics to forecast trends as well as boost growth.
Univar's shares have lost 17.8% in the past year compared with the industry’s 20.7% decline.
In March 2019, Univar provided updates on 2019 view, considering the recently completed buyout of Nexeo Solutions closed on Mar 1, 2019.
For 2019, it expects adjusted EBITDA between $740 million and $760 million on a combined basis. The projected 10-month earnings from the Nexeo Chemicals business and realized synergies are worth roughly $10 million. The company expects to generate $300-$350 million in free cash flow, before one-time integration cost of around $70 million.
Zacks Rank & Key Picks
Univar currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the basic materials space are Kirkland Lake Gold Ltd. , Ingevity Corporation (NGVT - Free Report) and Materion Corporation (MTRN - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Kirkland has an expected earnings growth rate of 8.8% for 2019. The company’s shares have surged 105.3% in the past year.
Ingevity has an expected earnings growth rate of 17.9% for the current year. The company’s shares have rallied 56.6% in a year’s time.
Materion has an expected earnings growth rate of 12.6% for 2019. Its shares have gained 11.6% in a year’s time.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>